Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing
2024-512669-15-00Phase 4Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in psoriatic arthritis (PsA), sponsored by Universitätsklinikum Erlangen. Primary endpoints: BOLD signal voxel count at week 1 compared to baseline and BOLD signal voxel count at week 12 compared to baseline. Started Mar 2024; status: completed.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2024-512669-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512669-15-00.